## Giorgio Zauli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4191716/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood, 2004, 104, 2418-2424.	1.4	422
2	Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging. Oncotarget, 2018, 9, 17181-17198.	1.8	303
3	Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7634-7639.	7.1	295
4	COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?. International Journal of Molecular Sciences, 2020, 21, 3474.	4.1	290
5	TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways. Circulation, 2003, 107, 2250-2256.	1.6	283
6	Cytokine Levels in the Serum of Healthy Subjects. Mediators of Inflammation, 2013, 2013, 1-6.	3.0	271
7	MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. Journal of Hematology and Oncology, 2017, 10, 133.	17.0	213
8	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 2010, 116, 945-952.	1.4	200
9	Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood, 2006, 107, 4122-4129.	1.4	156
10	Recent Advances in the Therapeutic Perspectives of Nutlin-3. Current Pharmaceutical Design, 2011, 17, 569-577.	1.9	150
11	Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice. Circulation, 2006, 114, 1522-1530.	1.6	147
12	NF-κB pathways in hematological malignancies. Cellular and Molecular Life Sciences, 2014, 71, 2083-2102.	5.4	140
13	In Vitro Senescence and Apoptotic Cell Death of Human Megakaryocytes. Blood, 1997, 90, 2234-2243.	1.4	133
14	An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction. American Journal of Pathology, 2006, 169, 2236-2244.	3.8	129
15	Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts. PLoS ONE, 2010, 5, e11140.	2.5	128
16	Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3. Circulation Research, 2007, 100, 61-69.	4.5	124
17	Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood, 2007, 110, 536-543.	1.4	121
18	The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine and Growth Factor Reviews, 2006, 17, 245-257.	7.2	120

#	Article	IF	CITATIONS
19	Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) Sequentially Upregulates Nitric Oxide and Prostanoid Production in Primary Human Endothelial Cells. Circulation Research, 2003, 92, 732-740.	4.5	119
20	Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. Journal of Cellular Physiology, 2004, 201, 331-340.	4.1	117
21	TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood, 2004, 103, 517-522.	1.4	110
22	TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood, 2004, 104, 2044-2050.	1.4	99
23	TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood, 2005, 105, 3413-3419.	1.4	98
24	lonizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood, 2001, 97, 2596-2603.	1.4	93
25	Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis, 2011, 215, 452-458.	0.8	90
26	Evidence for a Role of TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Anemia of Myelodysplastic Syndromes. American Journal of Pathology, 2005, 166, 557-563.	3.8	89
27	The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies. Current Pharmaceutical Design, 2008, 14, 2100-2110.	1.9	85
28	Tumor necrosis factor–related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood, 2002, 100, 2421-2429.	1.4	83
29	Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood, 2009, 113, 4300-4308.	1.4	83
30	Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction. PLoS ONE, 2009, 4, e4442.	2.5	82
31	Extracellular HIVâ€1 Tat protein activates phosphatidylinositol 3―and Akt/PKB kinases in CD4 <sup>+</sup> T lymphoblastoid Jurkat cells. European Journal of Immunology, 1997, 27, 2805-2811.	2.9	78
32	HIV-1 Tat-mediated Inhibition of the Tyrosine Hydroxylase Gene Expression in Dopaminergic Neuronal Cells. Journal of Biological Chemistry, 2000, 275, 4159-4165.	3.4	77
33	In vivo and in vitro inhibitory effect of α-interferon on megakaryocyte colony growth in essential thrombocythaemia. British Journal of Haematology, 1989, 71, 177-181.	2.5	76
34	Recombinant human immunodeficiency virus typeâ€l (HIVâ€l) Tat protein sequentially upâ€regulates ILâ€6 and TFGâ€Î²1 mRNA expression and protein synthesis in peripheral blood monocytes. British Journal of Haematology, 1994, 88, 261-267.	2.5	76
35	Impact of physical exercise in cancer survivors during and after antineoplastic treatments. Oncotarget, 2018, 9, 14005-14034.	1.8	71
36	Thrombopoietin Enhances the αIIbβ3-Dependent Adhesion of Megakaryocytic Cells to Fibrinogen or Fibronectin Through PI 3 Kinase. Blood, 1997, 89, 883-895.	1.4	70

#	Article	IF	CITATIONS
37	Role of full-length osteoprotegerin in tumor cell biology. Cellular and Molecular Life Sciences, 2009, 66, 841-851.	5.4	70
38	Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor–related apoptosis-inducing ligand–mediated cytotoxicity on hematologic malignancies. Blood, 2001, 98, 2220-2228.	1.4	69
39	Synergistic Cytotoxic Activity of Recombinant TRAIL Plus the Non-Genotoxic Activator of the p53 Pathway Nutlin-3 in Acute Myeloid Leukemia Cells. Current Drug Metabolism, 2007, 8, 395-403.	1.2	69
40	miR-34a Induces the Downregulation of Both <i>E2F1</i> and <i>B-Myb</i> Oncogenes in Leukemic Cells. Clinical Cancer Research, 2011, 17, 2712-2724.	7.0	69
41	Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. Journal of Neurochemistry, 2004, 86, 126-135.	3.9	67
42	Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Current Opinion in Hematology, 2008, 15, 42-48.	2.5	66
43	Extracellular Human Immunodeficiency Virus Type-1 Tat Protein Activates Phosphatidylinositol 3-Kinase in PC12 Neuronal Cells. Journal of Biological Chemistry, 1996, 271, 22961-22964.	3.4	65
44	PI-3K/Akt and NF-?B/I?B? pathways are activated in Jurkat T cells in response to TRAIL treatment. Journal of Cellular Physiology, 2005, 202, 900-911.	4.1	65
45	Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. Aids, 1993, 7, 1049-1056.	2.2	61
46	Nuclear translocation of protein kinase C-alpha and -zeta isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid. British Journal of Haematology, 1996, 93, 542-550.	2.5	61
47	TRAIL inhibits osteoclastic differentiation by counteracting RANKLâ€dependent p27 <sup>Kip1</sup> accumulation in preâ€osteoclast precursors. Journal of Cellular Physiology, 2008, 214, 117-125.	4.1	61
48	An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis, 2010, 210, 274-277.	0.8	61
49	Changes of Nuclear Protein Kinase C Activity and Isotype Composition in PC12 Cell Proliferation and Differentiation. Experimental Cell Research, 1996, 224, 72-78.	2.6	59
50	HIV Type 1 Extracellular Tat Protein Stimulates Growth and Protects Cells of BK Virus/ <i>tat</i> Transgenic Mice from Apoptosis. AIDS Research and Human Retroviruses, 1995, 11, 1039-1048.	1.1	58
51	Treatment With Recombinant Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Alleviates the Severity of Streptozotocin-Induced Diabetes. Diabetes, 2010, 59, 1261-1265.	0.6	58
52	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Promotes Migration of Human Bone Marrow Multipotent Stromal Cells. Stem Cells, 2008, 26, 2955-2963.	3.2	56
53	Evidence for a Proangiogenic Activity of TNF-Related Apoptosis-Inducing Ligand. Neoplasia, 2004, 6, 364-373.	5.3	55
54	HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity. Journal of Cellular Physiology, 2005, 203, 547-556.	4.1	54

#	Article	IF	CITATIONS
55	Impaired survival of bone marrow GPIIb/IIIa + megakaryocytic cells as an additional pathogenetic mechanism of HIVâ€lâ€related thrombocytopenia. British Journal of Haematology, 1996, 92, 711-717.	2.5	53
56	Ultrastructural characterization of maturation, platelet release, and senescence of human cultured megakaryocytes. The Anatomical Record, 2000, 258, 90-99.	1.8	52
57	Actively targeted nanocarriers for drug delivery to cancer cells. Expert Opinion on Drug Delivery, 2019, 16, 481-496.	5.0	52
58	IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells. , 1997, 30, 61-66.		51
59	Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. Atherosclerosis, 2011, 218, 61-68.	0.8	51
60	Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise. Oncotarget, 2018, 9, 17238-17254.	1.8	51
61	Tat-expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute human immunodeficiency virus-type 1 (HIV -1) infection. British Journal of Haematology, 1995, 89, 24-33.	2.5	50
62	Extracellular HIV-1 Tat protein differentially activates the JNK and ERK/MAPK pathways in CD4 T cells. Aids, 1999, 13, 1637-1645.	2.2	50
63	HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts. Scientific Reports, 2018, 8, 17665.	3.3	50
64	Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway. Clinical Cancer Research, 2011, 17, 762-770.	7.0	48
65	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Molecular and Cellular Endocrinology, 2014, 394, 13-20.	3.2	48
66	Tumor necrosis factor alpha (TNF-alpha) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 2002, 13, 13-8.	0.8	48
67	Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis. Nanoscale, 2013, 5, 7897.	5.6	47
68	5 Effect of human immunodeficiency virus infection on haematopoiesis. Best Practice and Research: Clinical Haematology, 1995, 8, 113-130.	1.1	46
69	Role of physical exercise in the regulation of epigenetic mechanisms in inflammation, cancer, neurodegenerative diseases, and aging process. Journal of Cellular Physiology, 2019, 234, 14852-14864.	4.1	45
70	The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica, 2012, 97, 1722-1730.	3.5	44
71	TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clinical Science, 2012, 123, 547-555.	4.3	44
72	Applications of nanoparticles in cancer medicine and beyond: optical and multimodalin vivoimaging, tissue targeting and drug delivery. Expert Opinion on Drug Delivery, 2015, 12, 1837-1849.	5.0	44

#	Article	IF	CITATIONS
73	Targeting mTOR in Acute Lymphoblastic Leukemia. Cells, 2019, 8, 190.	4.1	44
74	TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies. Current Pharmaceutical Design, 2004, 10, 3673-3681.	1.9	43
75	Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. American Journal of Pathology, 2005, 167, 1599-1607.	3.8	43
76	Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor β1, produced in normal amount, in patients with essential thrombocythaemia. British Journal of Haematology, 1993, 83, 14-20.	2.5	42
77	Endothelial Cells Obtained from Patients Affected by Chronic Venous Disease Exhibit a Pro-Inflammatory Phenotype. PLoS ONE, 2012, 7, e39543.	2.5	42
78	Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases. Oncotarget, 2018, 9, 17220-17237.	1.8	42
79	The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts. Neoplasia, 2007, 9, 853-861.	5.3	41
80	Involvement of the pathway phosphatidylinositol-3-kinase/AKT-1 in the establishment of the survival response to ionizing radiation. Cellular Signalling, 2001, 13, 369-375.	3.6	40
81	Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases. PLoS ONE, 2018, 13, e0193867.	2.5	40
82	Mouse peritoneal cells as a reservoir of late dendritic cell progenitors. British Journal of Haematology, 1999, 104, 111-118.	2.5	39
83	Infection of CD34+ hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). Blood, 2000, 96, 126-131.	1.4	39
84	Cell-Based Therapies for Diabetic Complications. Experimental Diabetes Research, 2012, 2012, 1-10.	3.8	39
85	Interleukinâ€2 activates nuclear phospholipaseâ€Cβ by mitogenâ€activated protein kinaseâ€dependent phosphorylation in human natural killer cells. FASEB Journal, 2001, 15, 1789-1791.	0.5	37
86	HIVâ€1 Tat protein downâ€regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3â€kinase/AKT/cyclic nucleoside phosphodiesterase pathway. FASEB Journal, 2001, 15, 483-491.	0.5	37
87	An Autocrine Loop of HIV Type-1 Tat Protein Responsible for the Improved Survival/Proliferation Capacity of Permanently Tat-Transfected Cells and Required for Optimal HIV-1 LTR Transactivating Activity. Journal of Acquired Immune Deficiency Syndromes, 1995, 10, 306???316.	0.3	36
88	Impaired telomerase activity in uninfected haematopoietic progenitors in HIV-1-infected patients. Aids, 1998, 12, 999-1005.	2.2	36
89	C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1–Dependent Pathway. Clinical Cancer Research, 2013, 19, 1949-1959.	7.0	36
90	Clinical perspectives of TRAIL: insights into central nervous system disorders. Cellular and Molecular Life Sciences, 2016, 73, 2017-2027.	5.4	36

#	Article	IF	CITATIONS
91	The Human Immunodeficiency Virus Type-1 (HIV-1) Tat Protein and Bcl-2 Gene Expression. Leukemia and Lymphoma, 1996, 23, 551-560.	1.3	35
92	Extracellular HIV-1 Tat Protein Induces a Rapid and Selective Activation of Protein Kinase C (PKC)-α, -ϵ, and -ζ Isoforms in PC12 Cells. Biochemical and Biophysical Research Communications, 1998, 242, 332-337.	2.1	35
93	Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation. Journal of Cellular Physiology, 2006, 206, 647-654.	4.1	35
94	TRAIL Modulates the Immune System and Protects against the Development of Diabetes. Journal of Immunology Research, 2015, 2015, 1-12.	2.2	35
95	Targeting the phosphatidylinositol 3â€kinase/Akt/mechanistic target of rapamycin signaling pathway in Bâ€lineage acute lymphoblastic leukemia: An update. Journal of Cellular Physiology, 2018, 233, 6440-6454.	4.1	35
96	Roles and clinical implications of microRNAs in acute lymphoblastic leukemia. Journal of Cellular Physiology, 2018, 233, 5642-5654.	4.1	35
97	PMAâ€induced megakaryocytic differentiation of HEL cells is accompanied by striking modifications of protein kinase C catalytic activity and isoform composition at the nuclear level. British Journal of Haematology, 1996, 92, 530-536.	2.5	34
98	Effect of different human immunodeficiency virus typeâ€1 (HIVâ€1) isolates on longâ€term bone marrow haemopoiesis. British Journal of Haematology, 1993, 85, 596-602.	2.5	34
99	Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Molecular and Cellular Endocrinology, 2011, 331, 136-142.	3.2	34
100	Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity. International Journal of Biochemistry and Cell Biology, 2016, 81, 364-374.	2.8	34
101	Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. Journal of Cellular Physiology, 2006, 207, 158-164.	4.1	33
102	Tumor necrosis factorâ€related apoptosisâ€inducing ligand (TRAIL) regulates endothelial nitric oxide synthase (eNOS) activity and its localization within the human vein endothelial cells (HUVEC) in culture. Journal of Cellular Biochemistry, 2006, 97, 782-794.	2.6	32
103	Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4+ T cells. Blood, 2001, 98, 2474-2481.	1.4	31
104	HIV-1 Tat Protects CD4+ Jurkat T Lymphoblastoid Cells from Apoptosis Mediated by TNF-Related Apoptosis-Inducing Ligand. Cellular Immunology, 2001, 207, 89-99.	3.0	31
105	State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 207-217.	1.6	31
106	Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood, 2008, 111, 1287-1294.	1.4	30
107	Metalloproteinase 2 cleaves in vitro recombinant TRAIL: Potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis, 2010, 211, 333-336.	0.8	30
108	Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. Human Reproduction, 2012, 27, 2941-2947.	0.9	30

#	Article	IF	CITATIONS
109	Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts. Clinical Cancer Research, 2013, 19, 3871-3880.	7.0	30
110	TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?. Clinical Science, 2019, 133, 1145-1166.	4.3	30
111	Kinetics of in vitro natural killer activity against K562 cells as detected by flow cytometry. , 1998, 32, 280-285.		29
112	Accumulation of catalytically active PKC-ζ into the nucleus of HL-60 cell line plays a key role in the induction of granulocytic differentiation mediated by all-transretinoic acid. British Journal of Haematology, 1998, 100, 541-549.	2.5	29
113	Human Herpesvirus 7 Infection Induces Profound Cell Cycle Perturbations Coupled to Disregulation of cdc2 and Cyclin B and Polyploidization of CD4+ T Cells. Blood, 1998, 92, 1685-1696.	1.4	29
114	Comparison between different laboratory tests for the detection and prevention of heparin-induced thrombocytopenia. Cytometry, 2001, 46, 290-295.	1.8	29
115	The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. Rheumatology, 2008, 48, 293-298.	1.9	29
116	In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome. PLoS ONE, 2013, 8, e56377.	2.5	29
117	Progressive and Persistent Downregulation of Surface CXCR4 in CD4+ T Cells Infected With Human Herpesvirus 7. Blood, 1998, 92, 4521-4528.	1.4	28
118	The MDM2 inhibitor Nutlin-3 modulates dendritic cell–induced T cell proliferation. Human Immunology, 2012, 73, 342-345.	2.4	28
119	The Induction of Megakaryocyte Differentiation Is Accompanied by Selective Ser133 Phosphorylation of the Transcription Factor CREB in Both HEL Cell Line and Primary CD34+Cells. Blood, 1998, 92, 472-480.	1.4	28
120	Human herpesvirus type 7 in Hodgkin's disease. British Journal of Haematology, 1998, 101, 492-499.	2.5	27
121	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-α promote the NF-κB-dependent maturation of normal and leukemic myeloid cells. Journal of Leukocyte Biology, 2003, 74, 223-232.	3.3	27
122	<i>MDM4 (MDMX)</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53 <sup>wildâ€type</sup> CLL with a poor cytotoxic response to Nutlinâ€3. British Journal of Haematology, 2010, 150, 237-239.	2.5	27
123	HIV-1 Tat induces tyrosine phosphorylation of p125FAK and its association with phosphoinositide 3-kinase in PC12 cells. Aids, 1998, 12, 1275-1284.	2.2	26
124	Differentially expressed genes in HIV-1 tat-expressing CD4+ T-cell line. Virus Research, 2002, 90, 337-345.	2.2	26
125	Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. Journal of Cellular Physiology, 2005, 205, 246-252.	4.1	26
126	Engagement of CD28 Modulates CXC Chemokine Receptor 4 Surface Expression in Both Resting and CD3-Stimulated CD4+ T Cells. Journal of Immunology, 2000, 164, 4018-4024.	0.8	25

#	Article	IF	CITATIONS
127	Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14620-14625.	7.1	25
128	Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development. Journal of Cellular Physiology, 2005, 204, 975-982.	4.1	25
129	The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. Acta Diabetologica, 2014, 51, 239-246.	2.5	25
130	Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1. Oncotarget, 2016, 7, 18965-18977.	1.8	25
131	Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB. Clinical Nutrition, 2013, 32, 259-264.	5.0	24
132	Endothelial PDGF-BB produced ex vivo correlates with relevant hemodynamic parameters in patients affected by chronic venous disease. Cytokine, 2013, 63, 92-96.	3.2	24
133	Modulation of Circulating Cytokine-Chemokine Profile in Patients Affected by Chronic Venous Insufficiency Undergoing Surgical Hemodynamic Correction. Journal of Immunology Research, 2014, 2014, 1-10.	2.2	24
134	Sex/Gender-Specific Imbalance in CVD: Could Physical Activity Help to Improve Clinical Outcome Targeting CVD Molecular Mechanisms in Women?. International Journal of Molecular Sciences, 2020, 21, 1477.	4.1	24
135	Essential thrombocythemia: Impaired regulation of megakaryocyte progenitors. International Journal of Cell Cloning, 1991, 9, 43-56.	1.6	23
136	Upregulation of c-Fos in Activated T Lymphoid and Monocytic Cells by Human Immunodeficiency Virus-1 Tat Protein. Blood, 1997, 89, 1654-1664.	1.4	23
137	Differential effects of stromal derived factor-1? (SDF-1?) on early and late stages of human megakaryocytic development. The Anatomical Record, 2000, 260, 141-147.	1.8	23
138	The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells. Clinical Cancer Research, 2010, 16, 1824-1833.	7.0	23
139	Multimodal near-infrared-emitting PluS Silica nanoparticles with fluorescent, photoacoustic, and photothermal capabilities. International Journal of Nanomedicine, 2016, Volume 11, 4865-4874.	6.7	23
140	Physical training interventions for children and teenagers affected by acute lymphoblastic leukemia and related treatment impairments. Oncotarget, 2018, 9, 17199-17209.	1.8	23
141	All-Trans Retinoic Acid and Induction of Apoptosis in Acute Promyelocytic Leukemia Cells. Leukemia and Lymphoma, 1994, 14, 503-507.	1.3	22
142	Differential production of IFN-?, analyzed at the single-cell level, by specific subsets of human NK and T cells from healthy and HIV+ subjects. , 2000, 39, 189-194.		22
143	Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro. Journal of Cellular Physiology, 2007, 212, 89-95.	4.1	22
144	MDM2 Antagonist Nutlin-3 Suppresses the Proliferation and Differentiation of Human Pre-Osteoclasts Through a p53-Dependent Pathway. Journal of Bone and Mineral Research, 2007, 22, 1621-1630.	2.8	22

#	Article	IF	CITATIONS
145	Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. Journal of Medicinal Chemistry, 2016, 59, 147-156.	6.4	22
146	Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Oncotarget, 2016, 7, 79842-79853.	1.8	22
147	Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. Oncotarget, 2014, 5, 4347-4360.	1.8	22
148	Increased serum levels of transforming growth factor β-1 in patients affected by thrombotic thrombocytopenic purpura (TTP): its implications on bone marrow haematopoiesis. British Journal of Haematology, 1993, 84, 381-386.	2.5	21
149	Association of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Central Adiposity and Low-Density Lipoprotein Cholesterol. PLoS ONE, 2013, 8, e58225.	2.5	21
150	Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. Oncotarget, 2016, 7, 70623-70638.	1.8	21
151	Role of HIV infection in the hematologic manifestations of HIV seropositive subjects. Critical Reviews in Oncology/Hematology, 1993, 15, 271-283.	4.4	20
152	The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. Acta Diabetologica, 2013, 50, 899-906.	2.5	20
153	SARS-CoV-2 nucleocapsid protein and ultrastructural modifications in small bowel of a 4-week-negative COVID-19 patient. Clinical Microbiology and Infection, 2021, 27, 936-937.	6.0	20
154	Stroma-derived factor 1alpha induces a selective inhibition of human erythroid development via the functional upregulation of Fas/CD95 ligand. British Journal of Haematology, 2000, 111, 432-440.	2.5	20
155	Lack of compensatory megakaryocytopoiesis in HIV-1-seropositive thrombocytopenic individuals compared with immune thrombocytopenic purpura patients. Aids, 1991, 5, 1345-1350.	2.2	19
156	Human megakaryocyte biology and pathophysiology. Critical Reviews in Oncology/Hematology, 1995, 21, 135-157.	4.4	19
157	Selective modulation of the cyclin B/CDK1 and cyclin D/CDK4 complexes during in vitro human megakaryocyte development. British Journal of Haematology, 1999, 104, 820-828.	2.5	19
158	TNF-α modulates the migratory response of mesenchymal stem cells to TRAIL. Cellular and Molecular Life Sciences, 2010, 67, 1307-1314.	5.4	19
159	Human papillomavirus infection is associated with decreased levels of GM-CSF in cervico-vaginal fluid of infected women. Journal of Clinical Virology, 2013, 58, 479-481.	3.1	19
160	The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. Oncotarget, 2017, 8, 59235-59245.	1.8	19
161	Inhibitory Effect of Natural Anti-Inflammatory Compounds on Cytokines Released by Chronic Venous Disease Patient-Derived Endothelial Cells. Mediators of Inflammation, 2013, 2013, 1-13.	3.0	18
162	Multiple dye-doped NIR-emitting silica nanoparticles for both flow cytometry and in vivo imaging. RSC Advances, 2014, 4, 18278-18285.	3.6	18

#	Article	IF	CITATIONS
163	Impaired GM-CSF production by cultured light density mononuclear cells and T lymphocytes correlates with the number of circulating CFU-gm in HTV-1 seropositive subjects. International Journal of Cell Cloning, 1991, 9, 239-250.	1.6	17
164	Progressive and Selective Impairment of IL-3 and IL-4 Production by Peripheral Blood CD4 <sup>+</sup> T-Lymphocytes During the Course of HIV-1 Infection. Viral Immunology, 1992, 5, 185-194.	1.3	17
165	The CD4 receptor plays essential but distinct roles in HIVâ€1 infection and induction of apoptosis in primary bone marrow GPIIb/IIIa <sup>+</sup> megakaryocytes and the HEL cell line. British Journal of Haematology, 1995, 91, 290-298.	2.5	17
166	Morphological features of osteoclasts derived from a co-culture system. Journal of Molecular Histology, 2006, 37, 171-177.	2.2	17
167	Nutlin-3 Downregulates the Expression of the Oncogene <i>TCL1</i> in Primary B Chronic Lymphocytic Leukemic Cells. Clinical Cancer Research, 2011, 17, 5649-5655.	7.0	17
168	In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. European Journal of Cancer & Clinical Oncology, 1989, 25, 1281-1286.	0.7	16
169	Characterization of the Effects of Two Polysulfonated Distamycin A Derivatives, PNU145156E and PNU153429, on HIV Type 1 Tat Protein. AIDS Research and Human Retroviruses, 1998, 14, 1561-1571.	1.1	16
170	TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse. Clinical Science, 2018, 132, 69-83.	4.3	16
171	Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients. Frontiers in Pharmacology, 2020, 11, 1156.	3.5	16
172	The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway. Oncotarget, 2015, 6, 2385-2396.	1.8	16
173	Tiazofurin Induces a Down-Modulation of ICAM-1 Expression on K562 Target Cells Impairing NK Adhesion and Killing. Cellular Immunology, 1995, 164, 100-104.	3.0	15
174	Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model. PLoS ONE, 2014, 9, e115387.	2.5	15
175	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget, 2017, 8, 23213-23227.	1.8	15
176	Different levels of the neuronal nitric oxide synthase isoform modulate the rate of osteoclastic differentiation of TIB-71 and CRL-2278 RAW 264.7 murine cell clones. The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, 2005, 286A, 945-954.	2.0	14
177	Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. Journal of Leukocyte Biology, 2008, 83, 434-437.	3.3	14
178	Allâ€ <i>trans</i> retinoic acid at low concentration directly stimulates normal adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. European Journal of Haematology, 1999, 63, 149-153.	2.2	14
179	SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. Investigational New Drugs, 2012, 30, 2403-2406.	2.6	14
180	Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. Journal of Clinical Virology, 2012, 55, 367-369.	3.1	14

#	Article	IF	CITATIONS
181	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. Journal of Hematology and Oncology, 2013, 6, 83.	17.0	14
182	The First Trimester Gravid Serum Regulates Procalcitonin Expression in Human Macrophages Skewing Their PhenotypeIn Vitro. Mediators of Inflammation, 2014, 2014, 1-10.	3.0	14
183	Inverse Correlation Between Circulating Levels of TNF-Related Apoptosis-Inducing Ligand and 17β-Estradiol. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E659-E664.	3.6	14
184	Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. PLoS ONE, 2018, 13, e0203716.	2.5	14
185	In Vitro Senescence and Apoptotic Cell Death of Human Megakaryocytes. Blood, 1997, 90, 2234-2243.	1.4	14
186	Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 55690-55703.	1.8	14
187	Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity. International Journal of Molecular Sciences, 2021, 22, 11241.	4.1	14
188	TNF-related apoptosis-inducing ligand (TRAIL) up-regulates cyclooxygenase (COX)-1 activity and PGE(2) production in cells of the myeloid lineage. Journal of Leukocyte Biology, 2002, 72, 986-94.	3.3	14
189	Lineage-related susceptibility of human hemopoietic cell lines to apoptosis. , 1999, 254, 1-6.		13
190	Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. Experimental Hematology, 2004, 32, 925-934.	0.4	13
191	The Italian law on body donation: A position paper of the Italian College of Anatomists. Annals of Anatomy, 2021, 238, 151761.	1.9	13
192	TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases. Current Drug Targets, 2012, 13, 1215-1221.	2.1	13
193	Selective modulation of specific protein kinase C (PKC) isoforms in primary human megakaryocytic vs. erythroid cells. , 1999, 255, 7-14.		12
194	Trail downâ€regulates the release of osteoprotegerin (OPG) by primary stromal cells. Journal of Cellular Physiology, 2011, 226, 2279-2286.	4.1	12
195	TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide. Cytokine, 2012, 60, 43-46.	3.2	12
196	Activation of the p53 pathway induces αâ€ <b>s</b> mooth muscle actin expression in both myeloid leukemic cells and normal macrophages. Journal of Cellular Physiology, 2012, 227, 1829-1837.	4.1	12
197	Lovastatin Dose-Dependently Potentiates the Pro-inflammatory Activity of Lipopolysaccharide Both In Vitro and In Vivo. Journal of Cardiovascular Translational Research, 2013, 6, 981-988.	2.4	12
198	Presence of CTAK/CCL27, MCP-3/CCL7 and LIF in human colostrum and breast milk. Cytokine, 2013, 61, 26-28.	3.2	12

#	Article	IF	CITATIONS
199	In VitroEndothelial Cell Proliferation Assay Reveals Distinct Levels of Proangiogenic Cytokines Characterizing Sera of Healthy Subjects and of Patients with Heart Failure. Mediators of Inflammation, 2014, 2014, 1-11.	3.0	12
200	HIV-1 gp120 induces the activation of both c-fos and c-jun immediate-early genes in HEL megakaryocytic cells. British Journal of Haematology, 1999, 104, 81-86.	2.5	11
201	Extracellular Tat activates c-fos promoter in low serum-starved CD4+ T cells. British Journal of Haematology, 2001, 112, 663-670.	2.5	11
202	TRAIL Activates a Caspase 9/7-Dependent Pathway in Caspase 8/10-Defective SK-N-SH Neuroblastoma Cells with Two Functional End Points: Induction of Apoptosis and PGE2 Release. Neoplasia, 2003, 5, 457-466.	5.3	11
203	Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. Journal of Cellular Physiology, 2007, 213, 229-236.	4.1	11
204	The Puzzling Role of TRAIL in Endothelial Cell Biology. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, e4; author reply e5-6.	2.4	11
205	Conjunctival sac fluid contains elevated levels of soluble TRAIL: Implications for the antiâ€ŧumoral surveillance of the anterior surface of the eye. Journal of Cellular Physiology, 2009, 218, 199-204.	4.1	11
206	Perifosine plus nutlinâ€3 combination shows a synergistic antiâ€leukaemic activity. British Journal of Haematology, 2010, 148, 957-961.	2.5	11
207	Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines. Investigational New Drugs, 2011, 29, 392-395.	2.6	11
208	The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans. Clinical Nutrition, 2012, 31, 1018-1021.	5.0	11
209	GM-CSF Exhibits Anti-Inflammatory Activity on Endothelial Cells Derived from Chronic Venous Disease Patients. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	11
210	Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3. Molecular Carcinogenesis, 2014, 53, 498-504.	2.7	11
211	Serum Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Levels in Older Subjects with Dementia and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2016, 41, 273-280.	1.5	11
212	Effects of Hypoxia and Bed Rest on Markers of Cardiometabolic Risk: Compensatory Changes in Circulating TRAIL and Glutathione Redox Capacity. Frontiers in Physiology, 2018, 9, 1000.	2.8	11
213	Dexamethasone counteracts the antiâ€osteoclastic, but not the antiâ€leukemic, activity of TNFâ€related apoptosis inducing ligand (TRAIL). Journal of Cellular Physiology, 2010, 222, 357-364.	4.1	10
214	Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus. Current Pharmaceutical Design, 2012, 18, 5759-5765.	1.9	10
215	Human Colostrum and Breast Milk Contain High Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL). Journal of Human Lactation, 2013, 29, 23-25.	1.6	10
216	Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cells. Nutrition, 2013, 29, 332-337.	2.4	10

#	Article	IF	CITATIONS
217	Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS). Genes, 2019, 10, 634.	2.4	10
218	Stromal derived factor-1α induces apoptosis in activated primary CD4+ T cells. Aids, 2000, 14, 748-750.	2.2	10
219	The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?. Rheumatology, 2010, 49, 1173-1176.	1.9	9
220	TRAIL treatment prevents renal morphological changes and TGF-Î <sup>2</sup> -induced mesenchymal transition associated with diabetic nephropathy. Clinical Science, 2020, 134, 2337-2352.	4.3	9
221	The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. Oncotarget, 2014, 5, 12635-12645.	1.8	9
222	TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases. Current Drug Targets, 2012, 13, 1089-1095.	2.1	8
223	TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress. Mediators of Inflammation, 2018, 2018, 1-8.	3.0	8
224	<scp>MCL</scp> 1 downâ€regulation plays a critical role in mediating the higher antiâ€leukaemic activity of the multiâ€kinase inhibitor <scp>S</scp> orafenib with respect to <scp>D</scp> asatinib. British Journal of Haematology, 2012, 157, 510-514.	2.5	7
225	Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Show a Long-term Stability in the Breast Milk of Mothers of Preterm Infants. Journal of Human Lactation, 2013, 29, 350-353.	1.6	7
226	Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival. Reproduction, 2014, 148, 191-198.	2.6	7
227	Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus. Acta Diabetologica, 2015, 52, 1003-1006.	2.5	7
228	Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin. Journal of Cellular and Molecular Medicine, 2008, 12, 1063-1065.	3.6	6
229	Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2010, 69, 1733-1734.	0.9	6
230	Circulating TRAIL Shows a Significant Post-Partum Decline Associated to Stressful Conditions. PLoS ONE, 2011, 6, e27011.	2.5	6
231	Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Investigational New Drugs, 2012, 30, 1731-1735.	2.6	6
232	Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women. Mediators of Inflammation, 2017, 2017, 1-8.	3.0	6
233	Enforced expression of humanbcl-2 in CD4+ T cells enhances human herpesvirus 7 replication and induction of cytopathic effects. European Journal of Immunology, 1998, 28, 1587-1596.	2.9	5
234	Letter by Secchiero and Zauli Regarding Article, "Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in <i>ldlr</i> <sup>(Ⱂ/Ⱂ)</sup> Mice― Circulation, 2008, 118, e18; author reply e19.	1.6	5

#	Article	IF	CITATIONS
235	Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opinion on Therapeutic Targets, 2011, 15, 931-942.	3.4	5
236	TRAIL, a New Weapon against Neointimal Hyperplasia. Cardiology, 2012, 123, 94-96.	1.4	5
237	JCV+ Patients with Inflammatory Bowel Disease show elevated plasma levels of MIG and SCF. Inflammatory Bowel Diseases, 2012, 18, 1194-1196.	1.9	5
238	TNF-Related Apoptosis Inducing Ligand in Ocular Cancers and Ocular Diabetic Complications. BioMed Research International, 2015, 2015, 1-8.	1.9	5
239	Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Investigational New Drugs, 2012, 30, 803-807.	2.6	4
240	The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells. Investigational New Drugs, 2013, 31, 458-460.	2.6	4
241	The Induction of Megakaryocyte Differentiation Is Accompanied by Selective Ser133 Phosphorylation of the Transcription Factor CREB in Both HEL Cell Line and Primary CD34+Cells. Blood, 1998, 92, 472-480.	1.4	4
242	TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake. Cell Death and Disease, 2021, 12, 1089.	6.3	4
243	The engagement of CD4 surface antigen in the HEL haemopoietic cell line upâ€regulates the transforming growth factorâ€Î²1 (TGFâ€Î²1) promoter activity. British Journal of Haematology, 1997, 97, 571-578.	2.5	3
244	Role of TRAIL in osteoclastogenesis. Blood, 2008, 111, 5413-5413.	1.4	3
245	In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. Investigational New Drugs, 2012, 30, 405-407.	2.6	3
246	<i><scp>ARHGDIA</scp></i> , a mutant <scp>TP</scp> 53â€associated Rho <scp>GDP</scp> dissociation inhibitor, is overâ€expressed in gene expression profiles of <i><scp>TP</scp>53</i> disrupted chronic lymphocytic leukaemia cells. British Journal of Haematology, 2013, 161, 596-599.	2.5	3
247	Heterogeneity of mesenchymal stromal cells in lymphoproliferative disorders. Frontiers in Bioscience - Landmark, 2014, 19, 139.	3.0	3
248	Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors—implications for therapeutic potential. Tumor Biology, 2016, 37, 11909-11916.	1.8	3
249	Inflammation and Cardiovascular Cross Talk in Ischemic Vascular Diseases. Mediators of Inflammation, 2017, 2017, 1-2.	3.0	3
250	Flow cytometric quantification of HIV-1 Tat protein in tat-transfected Jurkat T cell lines. Journal of Immunological Methods, 1998, 221, 107-117.	1.4	2
251	Editorial [Hot Topic: Innovative Therapeutical Approaches for Hematological Malignancies Based on Molecular Targeted Therapies (Executive Editor: Giorgio Zauli) ]. Current Pharmaceutical Design, 2008, 14, 2022-2022.	1.9	2
252	Reduced expression of cell cycleâ€associated genes in B lymphocytes purified from the peripheral blood of earlyâ€stage B chronic lymphocytic leukaemia patients. British Journal of Haematology, 2009, 145, 424-426.	2.5	2

#	Article	IF	CITATIONS
253	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	12.6	2
254	Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1. Investigational New Drugs, 2013, 31, 780-786.	2.6	2
255	The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newborns. Cytokine, 2013, 64, 51-53.	3.2	2
256	Circulating levels of <scp>TNF</scp> â€related apoptosis inducing ligand ( <scp>TRAIL</scp> ). Clinical Endocrinology, 2014, 80, 182-183.	2.4	2
257	Two-gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results. Molecular Medicine Reports, 2015, 12, 6128-6132.	2.4	2
258	Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy. Mediators of Inflammation, 2015, 2015, 1-7.	3.0	2
259	Association between thyroid hormones and TRAIL. Clinical Biochemistry, 2017, 50, 972-976.	1.9	2
260	Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors. Current Oncology, 2021, 28, 2439-2451.	2.2	2
261	Role of CREB transcription factor in c-fos activation in natural killer cells. , 2002, 32, 3358.		2
262	Extracellular HIV-1 Tat protein activates the transcriptional repressor inducible cAMP early repressor in both the Jurkat cell line and primary peripheral blood mononuclear cells. Aids, 2000, 14, 1059.	2.2	2
263	Simultaneous determination of multiple cytokines reveals a pro-inflammatory and pro-angiogenic signature after major cardiothoracic surgery: Potential role of C-reactive protein. Cytokine, 2012, 60, 593-595.	3.2	1
264	The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Investigational New Drugs, 2012, 30, 810-818.	2.6	1
265	Association of Serum Tumor Necrosis Factor-Related Apoptosis Inducing Ligand with Body Fat Distribution as Assessed by Dual X-Rays Absorptiometry. Mediators of Inflammation, 2014, 2014, 1-6.	3.0	1
266	Role of CREB transcription factor in c-fos activation in natural killer cells. European Journal of Immunology, 2002, 32, 3358-3365.	2.9	1
267	DIFFERENTIAL REGULATION OF BCL-2 AND C-FOS GENES BY HIV-1 TAT PROTEIN IN SERUM-STARVED AND ACTIVATED LYMPHOID T CELLS. Biochemical Society Transactions, 1996, 24, 593S-593S.	3.4	0
268	Selective enrichment in human megakaryocyte progenitors by the B203.13 surface differentiation antigen. British Journal of Haematology, 1997, 99, 766-769.	2.5	0
269	Stromaâ€derived factor 1α induces a selective inhibition of human erythroid development via the functional upregulation of Fas/CD95 ligand. British Journal of Haematology, 2000, 111, 432-440.	2.5	0
270	The long and winding road may be getting shorter. Blood, 2005, 105, 4160-4160.	1.4	0

#	Article	IF	CITATIONS
271	Potential involvement of TRAIL in Treg cell–mediated osteoclast suppression: Comment on the article by Zaiss et al. Arthritis and Rheumatism, 2008, 58, 1887-1887.	6.7	0
272	Editorial [Innovative Therapeutic Approaches for the Treatment of Pediatric Autoimmune and Inflammatory Diseases Executive (Guest Editor: Giorgio Zauli)]. Current Pharmaceutical Design, 2012, 18, 5728-5728.	1.9	0
273	B-Cell Chronic Lymphocytic Leukemia Cells Exposed to the Non-Genotoxic p53 Activator Nutlin-3 Are Characterized by a Specific Gene Expression Signature Blood, 2009, 114, 4374-4374.	1.4	0